Lead sponsor
Nanjing First Hospital, Nanjing Medical University
6 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
6
Trials led
2
Active
1,660
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Early Phase 1
1
Phase 3
1
Phase 4
1
Not applicable
3
Trials by status
Recruiting
2
Unknown
4
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes MellitusHbA1c ≥7.5%not applicableUnknown330
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 DiabetesBMI ≥23Ph 4Recruiting150
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 YearsBMI ≥24not applicableUnknown100